Strain-dependent disease and response to favipiravir treatment in mice infected with Chikungunya virus.
Chikungunya virus
Favipiravir
Mouse
Pathogenicity
Strain differences
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
15
04
2020
revised:
28
07
2020
accepted:
29
07
2020
pubmed:
14
8
2020
medline:
13
7
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Antiviral countermeasures are needed to reduce the morbidity associated with Chikungunya virus (CHIKV) infection. This arbovirus reemerged in 2004 and causes periodic outbreaks in various areas throughout the world. While infection is rarely lethal, the majority of people infected with the virus develop a hallmark arthralgia as well as other disease manifestations. The virus is classified within three phylogenetic groups, namely, West African, East/Central/South African (ECSA), and Asian. Six strains of CHIKV covering the three phylogenetic groups were studied for their replication in cell culture, their ability to cause disease in susceptible mouse strains and susceptibility to antiviral treatment. Differential replication kinetics were observed for various CHIKV isolates in cell culture, which coincided with a decreased sensitivity to antiviral treatment as compared with ECSA and Asian clade viruses. This was confirmed in mouse infection studies with severe disease observed in mice infected with West African clade viruses, mild disease phenotype after infection with Asian clade viruses and an intermediate disease severity associated with ECSA virus infection. We also tested a broadly active antiviral, Favipiravir (T-705), which activity was inversely proportional to disease severity. These data suggest that some clades of CHIKV may cause more severe disease and may be more difficult to treat.
Identifiants
pubmed: 32791074
pii: S0166-3542(20)30318-1
doi: 10.1016/j.antiviral.2020.104904
pmc: PMC7543030
mid: NIHMS1620172
pii:
doi:
Substances chimiques
Amides
0
Antiviral Agents
0
Pyrazines
0
favipiravir
EW5GL2X7E0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
104904Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201000039C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201000039I
Pays : United States
Organisme : NIAID NIH HHS
ID : N01AI15435
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Antiviral Res. 2018 May;153:85-94
pubmed: 29524445
Viruses. 2019 Aug 29;11(9):
pubmed: 31470643
Microbes Infect. 2009 Dec;11(14-15):1197-205
pubmed: 19737626
PLoS Pathog. 2008 Feb 8;4(2):e29
pubmed: 18282093
Am J Trop Med Hyg. 2019 May;100(5):1249-1257
pubmed: 30860010
PLoS Pathog. 2007 Dec;3(12):e201
pubmed: 18069894
mBio. 2018 Mar 6;9(2):
pubmed: 29511072
Arthritis Rheumatol. 2018 Apr;70(4):585-593
pubmed: 29266856
Antiviral Res. 2013 Nov;100(2):446-54
pubmed: 24084488
PLoS Negl Trop Dis. 2012;6(3):e1446
pubmed: 22479654
Antiviral Res. 2009 Jun;82(3):95-102
pubmed: 19428599
PLoS Pathog. 2011 Dec;7(12):e1002412
pubmed: 22174678
Open Forum Infect Dis. 2017 Dec 02;5(1):ofx259
pubmed: 29354659
Virology. 2012 Apr 10;425(2):103-12
pubmed: 22305131
Epidemiol Infect. 2009 Apr;137(4):534-41
pubmed: 18694529
Antiviral Res. 2018 Jan;149:113-117
pubmed: 28958920
Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618807580
pubmed: 30354193
PLoS One. 2018 May 10;13(5):e0196857
pubmed: 29746539
J Antimicrob Chemother. 2014 Oct;69(10):2770-84
pubmed: 24951535